Kezar Life Sciences, Inc. (KZR)

Market Cap	46.55M
Revenue (ttm)	n/a
Net Income (ttm)	-95.78M
Shares Out	7.30M
EPS (ttm)	-13.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	71,567
Open	6.49
Previous Close	6.52
Day's Range	6.35 - 6.75
52-Week Range	5.20 - 11.40
Beta	0.19
Analysts	Hold
Price Target	9.00 (+41.07%)
Earnings Date	Nov 12, 2024

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company’s lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 58
• Stock Exchange: NASDAQ
• Ticker Symbol: KZR
• Website: https://www.kezarlifesciences.com

Analyst Forecast

According to 2 analysts, the average rating for KZR stock is "Hold." The 12-month stock price forecast is $9.0, which is an increase of 41.07% from the latest price.

Price Target

$9.0

(41.07% upside)

Analyst Consensus: Hold